Skip to contentOpens in a new tab
Free feasibility study

Week by week

Your project in nine weeks

Six weeks from go-ahead to ranked candidate sequences. Nine weeks to binders validated in the laboratory.

You approve each stage before the next one starts.

  1. Days

    Feasibility

    What we do
    We score your antigen and target site, and return a compatibility verdict.
    What you get
    Free verdict in about 3 business days, yes or no.
    What can fail
    No usable structure, a flexible site or a sugar-covered surface: we say so in the free study, before you commit.

  2. Weeks 1-2

    Prototyping

    What we do
    A short scoping run on your target: we design the workflow and size the campaign.
    What you get
    A quote built on your target, not an average one.
    What can fail
    Designs can pass every computational filter and still come back non-binding when tested.

  3. Weeks 2-4

    Generative design

    What we do
    We generate binders for your chosen site, on a scaffold with clinical precedent.
    What you get
    Your choice of binding site, format and developability constraints.
    What can fail
    Each attempt has a success rate, not a guarantee, and some targets yield no binders.

  4. Weeks 4-5

    Computational triage

    What we do
    We filter on sequence flaws, structure and an independent second prediction.
    What you get
    50 to 200 candidates worth looking at closely.
    What can fail
    We report how many designs drop out at each stage, not only the survivors.

  5. Weeks 5-6

    Molecular dynamics

    What we do
    We simulate each shortlisted complex to see if it holds, before anything is made.
    What you get
    Ranked candidate sequences, each with its binding site.
    What can fail
    A design pipeline always returns ranked candidates, whether or not any work.

  6. Weeks 7-9

    Wet-lab validation

    What we do
    We make the best candidates and test binding, expression and behaviour in solution.
    What you get
    Laboratory binding data for the candidates we take forward.
    What can fail
    Binding is not function, and the gap between them is the norm. We validate binding to the purified target.

What you get

  • Ranked candidate sequences, each with its binding site.Week 6
  • A developability profile per candidate, aggregation, expression and specificity, checked during design.
  • Binding data, from the laboratory, for the candidates we take forward.Week 9
  • The design record, how each candidate was made, for your files and your counsel.

Full ownership. Sequences, data and intellectual property are yours.

What we need to start

The antigen sequence is enough. A structure helps. If a published antibody defines your binding site, its PDB structure entry is usually enough.

Free feasibility study

The answers in full: Antibody design service: the questions clients ask us most · How do I develop a nanobody against a patented epitope already claimed by a competitor?